أعرض في EDS

Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial

التفاصيل البيبلوغرافية
العنوان: Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial
المؤلفون: Anne Bergeron, Christophe Hennequin, Emmanuel Bergot, Cendrine Godet, P. Germaud, M. Pineau, Arnaud Bourdin, T. Jeanfaivre, Jacques Cadranel, B. Philippe, Vincent Cottin
المساهمون: Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Pierre et Marie Curie - Paris 6 (UPMC), Hopital Réné Dubos, Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Descartes - Paris 5 (UPD5), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Maladies Respiratoires (MONTIGNY LES METZ - Maladies Respiratoires), MONTIGNY LES METZ, Rétrovirus et Pathologie Comparée, Institut National de la Recherche Agronomique (INRA)-École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Ecole Nationale Vétérinaire de Lyon (ENVL)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS), Département de pneumologie, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Pfizer, Centre hospitalier universitaire de Nantes (CHU Nantes), MSD, Astellas, Gilead, Schering-Plough, Institut National de la Recherche Agronomique (INRA)-École pratique des hautes études (EPHE), Cadranel, Jacques, ProdInra, Migration
المصدر: European Journal of Clinical Microbiology and Infectious Diseases
European Journal of Clinical Microbiology and Infectious Diseases, 2012, 31 (11), ⟨10.1007/s10096-012-1690-y⟩
European Journal of Clinical Microbiology and Infectious Diseases, Springer Verlag, 2012, 31 (11), ⟨10.1007/s10096-012-1690-y⟩
European Journal of Clinical Microbiology & Infectious Diseases
European Journal of Clinical Microbiology and Infectious Diseases 11 (31), . (2012)
بيانات النشر: HAL CCSD, 2012.
سنة النشر: 2012
مصطلحات موضوعية: Male, Antifungal Agents, [SDV]Life Sciences [q-bio], Aspergillosis, Aspergillus fumigatus, 0302 clinical medicine, Clinical endpoint, heterocyclic compounds, 030212 general & internal medicine, Prospective Studies, Prospective cohort study, Aged, 80 and over, 0303 health sciences, biology, Chronic pulmonary aspergillosis, General Medicine, Middle Aged, 3. Good health, [SDV] Life Sciences [q-bio], Treatment Outcome, Infectious Diseases, cardiovascular system, Female, Radiography, Thoracic, medicine.drug, Adult, Microbiology (medical), medicine.medical_specialty, Drug-Related Side Effects and Adverse Reactions, Article, 03 medical and health sciences, Internal medicine, Multicenter trial, medicine, Humans, Aged, Voriconazole, 030306 microbiology, business.industry, Endoscopy, Triazoles, medicine.disease, biology.organism_classification, Surgery, Clinical trial, Pyrimidines, Chronic Disease, Pulmonary Aspergillosis, business, Tomography, X-Ray Computed
الوصف: Early evidence suggests the efficacy of voriconazole for chronic pulmonary aspergillosis (CPA). We conducted a prospective, open, multicenter trial to evaluate the efficacy and safety of voriconazole for proven CPA in minimally or non-immunocompromised patients. Patients had CPA confirmed by chest computed tomography (CT) and/or endoscopy, positive Aspergillus culture from a respiratory sample, and positive serologic test for Aspergillus precipitins. Patients received voriconazole (200 mg twice daily) for a period of 6–12 months and were followed for 6 months after the end of therapy (EOT). The primary endpoint was global success at 6 months, defined as complete or partial (≥50 % improvement) radiological response and mycological eradication. Forty-one patients with confirmed CPA were enrolled. All patients had A. fumigatus as the etiologic agent. By EOT, five patients had died from comorbidities and seven had discontinued voriconazole due to toxicity. The global success rate at 6 months was 13/41 (32 %): 10/19 (53 %) for chronic necrotizing aspergillosis and 3/22 (14 %) for chronic cavitary aspergillosis (p = 0.01). The respective success rates at EOT were 58 and 32 %. Clinical symptoms and quality of life also improved during treatment. Voriconazole is effective for CPA, with acceptable toxicity. The response rate is higher and obtained more rapidly in necrotizing than cavitary forms. Electronic supplementary material The online version of this article (doi:10.1007/s10096-012-1690-y) contains supplementary material, which is available to authorized users.
وصف الملف: application/pdf
اللغة: English
تدمد: 0934-9723
1435-4373
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::126f5253b61945236077fcb975759322
https://hal.inrae.fr/hal-02651548
حقوق: OPEN
رقم الأكسشن: edsair.doi.dedup.....126f5253b61945236077fcb975759322
قاعدة البيانات: OpenAIRE
الوصف
تدمد:09349723
14354373